Heart Failure

A new tool may enable earlier identification of heart failure, potentially reducing hospitalizations and premature death.

This FDA News Month in Review provides a round-up of regulatory decisions and submissions from January 2025.

Only 7% of patients presenting to US emergency departments received cardiac biomarker testing, with 2.8% diagnosed with ACS.

The regulatory agency has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 14, 2025.

Medicaid-insured heart transplant recipients reported worse survival and higher risk of cardiac allograft vasculopathy over 5 years.

In this episode, hosts explore the latest updates to the ADA Standards of Care on therapeutic innovations and their real-world impact on diabetes management.

Grade 2 or 3 cardiac uptake showed a 5-fold higher risk of cardiovascular death compared to grade 1 in asymptomatic ATTR cardiac amyloid infiltration.

Increases in oxidized HDL levels were linked to HFpEF in new analyses, suggesting reduced antioxidant HDL function is present in this patient population.

Aspirin avoidance remained safe and did not increase thrombosis risk after LVAD implantation in patients with a history of atherosclerotic vascular conditions.

Submission of the supplemental NDA was based on positive findings from the FINEARTS-HF trial investigating finerenone for heart failure with an LVEF ≥40%.

Potassium nitrate increased blood nitric oxide metabolites but showed no improvement in exercise tolerance or quality of life in a population with HFpEF.

This listicle highlights 5 major approvals and 5 trial updates in cardiovascular care from 2024.

To celebrate the close of 2024, we surveyed top cardiologist on what they view as the biggest storyline in their field from the past year.

Orly Vardeny, PharmD, MS explores the efficacy of nonsteroidal MRAs in heart failure with mildly reduced or preserved ejection fraction in the FINE-ARTS trial.

Erin Michos, MD examines unique HFpEF mechanisms for women and implications for sex-specific treatment.

A look into how SGLT2 inhibitors, GLP-1 RAs, and nsMRAs have redefined the management of cardio-kidney-metabolic diseases.

Phase 1/2 data prompted the RMAT designation for HLHS shortly after Mesoblast announced positive phase 3 data for HFrEF.

Anemia in heart failure with preserved ejection fraction was linked to right ventricular dysfunction in an analysis of more than 1000 patients in China.

Our Cardiology Month in Review for November 2024 spotlights the approval of acoramidis and top content from AHA 2024.

David G. Armstrong, DPM, PhD, and Michael S. Conte, MD discuss Phase 2 results on anatomically directed lower extremity gene therapy for ulcer healing.

With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.

Ahmad Masri, MD, MS, discusses data from the FOREST-HCM trial examining effects of aficamten in patients with oHCM eligible for septal reduction therapy at baseline.

Ahmad Masri, MD, MS, discusses a study from AHA 2024 detailing changing risk profiles and outcomes in trials among patients with ATTR-CM.

In this episode, hosts break down a pair of studies from AHA 2024, BPROAD and SUMMIT, as well as a study in JAMA projecting semaglutide eligibility in US adults.

Marianna Fontana, MD, PhD discusses Phase 1 interim results on the CRISPR-based gene-editing therapy, nex-z, for ATTR-CM.